FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014453247> ?p ?o ?g. }

• W2014453247 endingPage "32" @default.
• W2014453247 startingPage "27" @default.
• W2014453247 abstract "The poor solubility and low dissolution rate in gastro-intestinal fluid, especially for class-II drugs according to Biopharmaceutics Classification System (BCS) the bioavailability enhanced by increasing the solubility and dissolution rate. A novel melt sonocrystallization technique of particle engineering to enhance solubility as well as dissolution of hydrophobic drug and to study its effect on crystal properties of drug. The present study leads to use investigate solubility of melt sonocrystallization technique to modify the undesirable properties of Rosiglitazone is antidiabetic drug in thiozolidione category with (BCS II) to forms agglomerates with number of shallow circular pits on the surface leads to increase solubility. Melt sonocrystallization process was developed for Rosiglitazone in which Rosiglitazone melt was poured in deionized water and simultaneously subjected to ultrasonic energy for 20 min at amplitude 80 %. The product obtained was evaluated using scanning electron microscopy, differential scanning calorimetry, X-ray powder diffractometry (XPRD), Fourier transformed infrared spectroscopy (FTIR), solubility and dissolution rate. The irregular agglomerates with porous surface were obtained having different crystal habit which increases solubility and dissolution rate. FTIR shows thermal behavior of untreated Rosiglitazone and treated Rosiglitazone have no significant difference low intensity peaks in XPRD of treated Rosiglitazone were noticed crystals habit changes and lattice defects during processing have causes favorable changes in the physicochemical properties of Rosiglitazone. The use of melt sonocrystallization technique is promising technique that may affords powder with improved flow as well as improved solubility and dissolution. La scarsa solubilità e il basso tasso di dissoluzione nei liquidi gastro-intestinali, soprattutto per farmaci di classe II secondo il Biopharmaceutics Classification System (BCS) richiede, per la biodisponiblità, un aumentando della solubilità e velocità di dissoluzione. Valutiamo una nuova tecnica di ingegneria delle particelle di scioglimento per sonocristallizazione per migliorare la solubilità, nonché la dissoluzione del farmaco e il suo effetto sulle proprietà cristalline del farmaco. Il presente studio indaga quindi la tecnica di scioglimento per sonocristallizazione per modificare la solubilità e le proprietà indesiderabili del Rosiglitazone, farmaco antidiabetico della categoria dei thiozolidione (BCS II) con la formazione di depressioni circolari poco profonde sulla superficie, per aumentare la solubilità. Il processo di scioglimento per sonocristallizazione è stato sviluppato per il Rosiglitazone. In questo esperimento il Rosiglitazone è stato versato in acqua deionizzata e contemporaneamente sottoposto a energia ad ultrasuoni per 20 min. con ampiezza all’ 80 %. Il prodotto ottenuto è stato valutato mediante microscopia elettronica a scansione (SEM), calorimetria differenziale a scansione (DSC), raggi X a diffrazione (XPRD), trasformata di Fourier con spettroscopia ad infrarossi (FTIR), solubilità e velocità di dissoluzione. Sono stati ottenuti agglomerati irregolari, con superficie porosa con diverso aspetto cristallino, che aumenta la solubilità e di dissoluzione. La FTIR mostra un comportamento termico del Rosiglitazone non trattato e trattato senza alcuna differenza significativa, picchi di bassa intensità del Rosiglitazone trattato sono stati notati in XPRD con cambiamenti cambiamenti favorevoli delle proprietà fisico-chimiche del Rosiglitazone. L’uso della tecnica scioglimento con sonocristallizazione è una tecnica promettente un migliore flusso e migliore solubilità e dissoluzione." @default.
• W2014453247 created "2016-06-24" @default.
• W2014453247 creator A5002527790 @default.
• W2014453247 creator A5015354432 @default.
• W2014453247 creator A5034771235 @default.
• W2014453247 date "2014-02-27" @default.
• W2014453247 modified "2023-10-18" @default.
• W2014453247 title "Solubility enhancement of rosiglitazone by using melt sonocrystallization technique" @default.
• W2014453247 cites W2030951340 @default.
• W2014453247 cites W2044594845 @default.
• W2014453247 cites W2047830588 @default.
• W2014453247 cites W2048360669 @default.
• W2014453247 cites W2056477334 @default.
• W2014453247 cites W2063454088 @default.
• W2014453247 cites W2071876860 @default.
• W2014453247 cites W2072508698 @default.
• W2014453247 cites W2076633179 @default.
• W2014453247 cites W2132497207 @default.
• W2014453247 cites W2138842915 @default.
• W2014453247 cites W2320457949 @default.
• W2014453247 doi "https://doi.org/10.1007/s40477-014-0074-9" @default.
• W2014453247 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3945191" @default.
• W2014453247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24616749" @default.
• W2014453247 hasPublicationYear "2014" @default.
• W2014453247 type Work @default.
• W2014453247 sameAs 2014453247 @default.
• W2014453247 citedByCount "9" @default.
• W2014453247 countsByYear W20144532472015 @default.
• W2014453247 countsByYear W20144532472016 @default.
• W2014453247 countsByYear W20144532472018 @default.
• W2014453247 countsByYear W20144532472020 @default.
• W2014453247 countsByYear W20144532472021 @default.
• W2014453247 countsByYear W20144532472022 @default.
• W2014453247 countsByYear W20144532472023 @default.
• W2014453247 crossrefType "journal-article" @default.
• W2014453247 hasAuthorship W2014453247A5002527790 @default.
• W2014453247 hasAuthorship W2014453247A5015354432 @default.
• W2014453247 hasAuthorship W2014453247A5034771235 @default.
• W2014453247 hasBestOaLocation W20144532472 @default.
• W2014453247 hasConcept C121332964 @default.
• W2014453247 hasConcept C127413603 @default.
• W2014453247 hasConcept C13965031 @default.
• W2014453247 hasConcept C155574463 @default.
• W2014453247 hasConcept C159985019 @default.
• W2014453247 hasConcept C160892712 @default.
• W2014453247 hasConcept C170493617 @default.
• W2014453247 hasConcept C178790620 @default.
• W2014453247 hasConcept C181389837 @default.
• W2014453247 hasConcept C185592680 @default.
• W2014453247 hasConcept C192562407 @default.
• W2014453247 hasConcept C203036418 @default.
• W2014453247 hasConcept C26771246 @default.
• W2014453247 hasConcept C2780152017 @default.
• W2014453247 hasConcept C39519442 @default.
• W2014453247 hasConcept C42360764 @default.
• W2014453247 hasConcept C43617362 @default.
• W2014453247 hasConcept C55493867 @default.
• W2014453247 hasConcept C71924100 @default.
• W2014453247 hasConcept C79191725 @default.
• W2014453247 hasConcept C88380143 @default.
• W2014453247 hasConcept C97355855 @default.
• W2014453247 hasConcept C98274493 @default.
• W2014453247 hasConceptScore W2014453247C121332964 @default.
• W2014453247 hasConceptScore W2014453247C127413603 @default.
• W2014453247 hasConceptScore W2014453247C13965031 @default.
• W2014453247 hasConceptScore W2014453247C155574463 @default.
• W2014453247 hasConceptScore W2014453247C159985019 @default.
• W2014453247 hasConceptScore W2014453247C160892712 @default.
• W2014453247 hasConceptScore W2014453247C170493617 @default.
• W2014453247 hasConceptScore W2014453247C178790620 @default.
• W2014453247 hasConceptScore W2014453247C181389837 @default.
• W2014453247 hasConceptScore W2014453247C185592680 @default.
• W2014453247 hasConceptScore W2014453247C192562407 @default.
• W2014453247 hasConceptScore W2014453247C203036418 @default.
• W2014453247 hasConceptScore W2014453247C26771246 @default.
• W2014453247 hasConceptScore W2014453247C2780152017 @default.
• W2014453247 hasConceptScore W2014453247C39519442 @default.
• W2014453247 hasConceptScore W2014453247C42360764 @default.
• W2014453247 hasConceptScore W2014453247C43617362 @default.
• W2014453247 hasConceptScore W2014453247C55493867 @default.
• W2014453247 hasConceptScore W2014453247C71924100 @default.
• W2014453247 hasConceptScore W2014453247C79191725 @default.
• W2014453247 hasConceptScore W2014453247C88380143 @default.
• W2014453247 hasConceptScore W2014453247C97355855 @default.
• W2014453247 hasConceptScore W2014453247C98274493 @default.
• W2014453247 hasIssue "1" @default.
• W2014453247 hasLocation W20144532471 @default.
• W2014453247 hasLocation W20144532472 @default.
• W2014453247 hasLocation W20144532473 @default.
• W2014453247 hasLocation W20144532474 @default.
• W2014453247 hasOpenAccess W2014453247 @default.
• W2014453247 hasPrimaryLocation W20144532471 @default.
• W2014453247 hasRelatedWork W2014453247 @default.
• W2014453247 hasRelatedWork W2057211131 @default.
• W2014453247 hasRelatedWork W2195160626 @default.
• W2014453247 hasRelatedWork W2407055192 @default.
• W2014453247 hasRelatedWork W2899714901 @default.
• W2014453247 hasRelatedWork W2910597072 @default.

• next